Gujarat Themis Biosyn Limited has raised ₹750 crore from a qualified institutions placement of equity shares made to qualified institutional buyers outside the United States.
Trilegal advised Gujarat Themis Biosyn on this QIP.
The transaction was led by Richa Choudhary (Partner) and Maitreya Rajurkar (Partner), with support from Avanti Kale (Counsel), Aayush Khandelwal (Senior Associate), Associates Siddhant Mishra, Naman Shah and Adya Singh.
CMS INDUSLAW advised the placement agents, namely Nuvama Wealth Management Limited, 360 ONE WAM Limited and Saffron Capital Advisors Private Limited, on this QIP.
The transaction was led by Kaushik Mukherjee (Partner) and Kanika Sachdeva (Partner), with support from Associates Yash Chhikara, Vaishnavi Tiwari, Aroosh Tarwani, Vikhyaat Maheshwari and Dhairya Gawde, and Associate Trainees Roshan Bali and Janhavi Deo Yadav.
Gujarat Themis is a fermentation-based pharmaceuticals company and has expertise across fermentation processes, product development and commercial manufacturing. Gujarat Themis is also among the largest manufacturers of Rifamycin intermediates in India and the first to commence commercial production of Rifamycin intermediates.
The QIP proceeds have been proposed to fund the overseas acquisition of MicroBiopharm Japan Co. Ltd.
If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.